In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Spinmeisters

Executive Summary

Spin-offs are beginning to look like an industry cure-all.

You may also be interested in...



The Resurrection of Affymax

A group of venture firms decided to buy Affymax from GSK at a bargain-basement valuation. They felt it had not merely the makings of a product company but could jumpstart the creation of a fully integrated biology/screening/chemistry drug discovery company. In effect, they bought, at a discount, a proto-Vertex that wouldn't have to wait nearly a decade to see a valuation explosion.

Coronavirus Update: After 'Warp Speed' Snub, Novavax Awarded US Military Vaccine Deal

Progress for two US-based companies in the race to develop a COVID-19 vaccine.

Aurobindo Upbeat On Outlook, Transfers Biologics Biz

After double-digit growth in formulation sales across geographies in the fourth quarter, Aurobindo expects to continue the momentum this fiscal year. Meanwhile, it might look for partners for its biologics business, which is now transferred to its fully owned subsidiary for $48m.    

Topics

Related Companies

UsernamePublicRestriction

Register

LL1126129

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel